BioSpace News Archive

- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for o

TheraLight, LLC, a privately held U.S.-based medical device company specializing in photomedicine, announced the relocation and expansion of its corporate headquarters to a new office and warehouse in Lindon, Utah to advance the operations and growth of the company.

Syros to Present at 39 th Annual J.P. Morgan Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021. Details for all three investor conferences are as follows: 39th Annual J.P. Morgan Healthcare Conference - C

Q BioMed Inc., a commercial stage biotech company, announced that the Centers for Medicare and Medicaid Services updated the Outpatient Prospective Payment System reimbursement rate for its FDA approved non-opioid metastatic bone pain drug Strontium89 on January 3, 2021.

QT Imaging™, developer of the QTscan®, has selected Freedom Ventures B.V., as the exclusive distributor of its 3D breast imaging technology for the European, Middle Eastern and North African markets.

Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the close of a Series BB financing totaling $38.5 million .

Increasing number of patients using advanced nutritional products and rising pervasiveness of chronic conditions are primarily driving global clinical nutrition market growth.

The cancer biological therapy market has witnessed the impact of rising incidences of cancer and a growing number of geriatric populations globally. Older people in the age group of 50 or more possess a high vulnerability to cancer.

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the 2021 BioConnect Virtual Conference hosted by H.C. Wainwright.